Model Medicines’ four-part conversation with David Moskowitz of 8VC offers an early investor perspective on the company’s founding vision, scientific opportunity, and role within a rapidly evolving Bio-IT landscape. As one of Model Medicines’ investors, 8VC brought a thesis-driven view of how computation, biology, and entrepreneurship could come together to create a new generation of therapeutics companies.

Episode 1, “From Research to Investing,” traces Moskowitz’s path from scientific research into venture investing, setting the foundation for how he evaluates breakthrough opportunities at the intersection of technology and biology.

Episode 2, “8VC’s Bio-IT Investments,” expands the conversation to 8VC’s broader investment thesis in Bio-IT, exploring why the firm sees biology and information technology as increasingly inseparable forces in healthcare innovation.

Episode 3, “Investing in Model Medicines,” focuses directly on Model Medicines, highlighting what drew 8VC to the company’s platform, team, and potential to apply AI to drug discovery in a fundamentally different way.

Episode 4, “AI and the Future of Drug Discovery,” looks ahead to how artificial intelligence could reshape therapeutic discovery, development timelines, and the way new medicines are brought forward.

Together, the series captures a formative moment in Model Medicines’ story: an investor-backed belief that AI could move beyond incremental efficiency and become a powerful engine for discovering new medicines.